Post by Rocky Mountain Cancer Centers

At the 2026 ASCO Annual Meeting, RMCC hematologist Dr. John Burke spoke with The ASCO Post about new research focused on diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma. The study explored whether adding two medications to the current standard treatment could help patients with high-risk disease live longer without their cancer progressing—and the results were encouraging. Learn about Dr. Burke’s perspective on these findings and their potential impact on lymphoma care in the full interview.